PDS Biotechnology Reports Financial Results for the Second Quarter 2020 and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. KNX
10. KMI

Go back to PDS Biotechnology Reports Financial Results for the Second Quarter 2020 and Provides Business Update

PDS Biotechnology (PDSB) Tops Q2 EPS by 4c

August 13, 2020 6:02 AM EDT

PDS Biotechnology (NASDAQ: PDSB) reported Q2 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23).

Second Quarter 2020 and Recent Business Highlights

Announced publication of PDS0101 triple combination preclinical study by the National Cancer Institute;Initiated Phase 2 clinical trial of PDS0101 triple combination, led by the National Cancer Institute, for the treatment of advanced human papillomavirus (HPV)-associated cancers;Announced Phase 2 trial to evaluate PDS0101 in combination with standard of care for treatment of locally advanced cervical cancer at The University of Texas MD Anderson Cancer Center;Launched novel PDS Biotech-owned vaccine... More